His primary areas of investigation include Internal medicine, Head and neck cancer, Surgery, Oncology and Radiation therapy. His research in Cancer, Chemotherapy, Cetuximab, Carcinoma and Phases of clinical research are components of Internal medicine. He usually deals with Cetuximab and limits it to topics linked to Survival analysis and Hazard ratio and Nimotuzumab.
His Head and neck cancer study combines topics from a wide range of disciplines, such as Swallowing, Quality of life, Nuclear medicine, Stage and Performance status. His Surgery research includes themes of Gastroenterology and Epidermoid carcinoma. His work carried out in the field of Oncology brings together such families of science as Clinical endpoint and Clinical trial.
Merrill S. Kies mostly deals with Internal medicine, Oncology, Surgery, Chemotherapy and Head and neck cancer. His Cancer, Phases of clinical research, Induction chemotherapy and Cetuximab study in the realm of Internal medicine connects with subjects such as In patient. The various areas that Merrill S. Kies examines in his Oncology study include Head and neck squamous-cell carcinoma, Cisplatin, Epidermal growth factor receptor and Head and neck.
The Surgery study combines topics in areas such as Gastroenterology and Carcinoma, Epidermoid carcinoma. Merrill S. Kies has included themes like Regimen, Concomitant and Toxicity in his Chemotherapy study. His Head and neck cancer study combines topics in areas such as Quality of life, Swallowing and Clinical trial.
Merrill S. Kies focuses on Internal medicine, Oncology, Cancer, Surgery and Radiation therapy. Merrill S. Kies combines subjects such as Head and neck squamous-cell carcinoma and Cetuximab with his study of Oncology. Merrill S. Kies works mostly in the field of Cetuximab, limiting it down to topics relating to Carboplatin and, in certain cases, Mucositis.
His study in Cancer is interdisciplinary in nature, drawing from both Larynx and Clinical endpoint. In his study, Chemoradiotherapy, Gene, MYB, Fusion transcript and Fusion gene is strongly linked to Adenoid cystic carcinoma, which falls under the umbrella field of Surgery. His Radiation therapy research is multidisciplinary, relying on both Complete blood count, Systemic therapy and Hazard ratio.
Merrill S. Kies mainly focuses on Surgery, Internal medicine, Radiation therapy, Oncology and Cancer. His research related to Phases of clinical research and Chemotherapy might be considered part of Internal medicine. His study explores the link between Radiation therapy and topics such as Hazard ratio that cross with problems in Head and neck, Merkel cell carcinoma, Neck dissection, Head neck and Adjuvant therapy.
The concepts of his Oncology study are interwoven with issues in Phase i trials and Targeted therapy. His study in the fields of Locally advanced and Conditional survival under the domain of Cancer overlaps with other disciplines such as Risk model. Merrill S. Kies focuses mostly in the field of Radiology, narrowing it down to topics relating to Feeding tube and, in certain cases, Head and neck cancer.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner;Paul M. Harari;Jordi Giralt;Nozar Azarnia.
The New England Journal of Medicine (2006)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study
Ezra E.W. Cohen;Lee S. Rosen;Everett E. Vokes;Merrill S. Kies.
Journal of Clinical Oncology (2008)
Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results
Hope S. Rugo;Roy S. Herbst;Glenn Liu;John W. Park.
Journal of Clinical Oncology (2005)
Head and Neck Cancers, Version 2.2014
David G. Pfister;Sharon Spencer;David M. Brizel;Barbara Burtness.
Journal of The National Comprehensive Cancer Network (2014)
Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck
Roy S. Herbst;Matthew Arquette;Dong M. Shin;Karel Dicke.
Journal of Clinical Oncology (2005)
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
Mark A. Socinski;Michael J. Schell;Amy Peterman;Kamal Bakri.
Journal of Clinical Oncology (2002)
Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience
B. Brockstein;D. J. Haraf;Alfred W Rademaker;M. S. Kies.
Annals of Oncology (2004)
Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911
Corey J. Langer;Jonathan Harris;Eric M. Horwitz;Nicos Nicolaou.
Journal of Clinical Oncology (2007)
Head and Neck Cancers
David G. Pfister;Kie Kian Ang;David M. Brizel;Barbara A. Burtness.
Journal of The National Comprehensive Cancer Network (2011)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: